News
Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...
Novo Nordisk faces challenges in the competitive GLP-1 market, but its strong brand and R&D create opportunities for ...
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
Zacks Investment Research on MSN10h
Amgen vs. Novo Nordisk: Which Pharma Giant Is the Better Buy?Amgen AMGN and Novo Nordisk NVO are among the largest companies in the pharmaceutical space. Amgen boasts one of the largest ...
Novo Nordisk A/S (NYSE:NVO) is one of the stocks that Jim Cramer shed light on. A caller asked about the stock’s status, and Cramer replied: “I want you to know I don’t want Novo Nordisk… and the ...
The city wins the 2025 Community Challenge $100,000 grand prize TORONTO, July 22, 2025 /CNW/ – Richmond, B.C. has been named ...
The Novo Nordisk Foundation and the Danish State Loan Fund announced on Thursday that they are investing in the world’s most ...
The Novo Nordisk Foundation's latest round of R&D funding will go towards projects in biomanufacturing, cardiometabolic diseases, and AI.
The latest international Novo Nordisk A/S news and views from Reuters - one of the world's largest news agencies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback